The binding of programmed cell death protein ligand 1 (PD-L1) to programmed cell death protein 1 (PD-1) leads to the blockade of immune cell activity and impairs T-cell-mediated immune responses, often resulting in the failure of tumour immunotherapy. Here, PDCD1 is linked to neoplasm.